[go: up one dir, main page]

RU2012129350A - COMBINED THERAPY USING ALPHA 5BETA1 ANTAGONISTS - Google Patents

COMBINED THERAPY USING ALPHA 5BETA1 ANTAGONISTS Download PDF

Info

Publication number
RU2012129350A
RU2012129350A RU2012129350/10A RU2012129350A RU2012129350A RU 2012129350 A RU2012129350 A RU 2012129350A RU 2012129350/10 A RU2012129350/10 A RU 2012129350/10A RU 2012129350 A RU2012129350 A RU 2012129350A RU 2012129350 A RU2012129350 A RU 2012129350A
Authority
RU
Russia
Prior art keywords
antibody
subject
disease
atcc
antagonist
Prior art date
Application number
RU2012129350/10A
Other languages
Russian (ru)
Inventor
Анан ЧУНТХАРАПАЙ
Грег ПЛАУМАН
Марк ТЕССЬЕ-ЛАВИНЬ
Янь У
Вэйлань Е
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2012129350A publication Critical patent/RU2012129350A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)

Abstract

1. Антитело, которое способно связывать человеческий альфа5бета1 и конкурентно подавлять связывание антитела против альфа5бета1 с человеческим альфа5бета1, где антитела против альфа5бета1 продуцируются гибридомой, выбранной из группы, состоящей из гибридомы, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) и гибридомы, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.2. Антитело по п.1, где антитело продуцируется гибридомой, выбранной из группы, состоящей из гибридомы, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) и гибридомы, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.3. Антитело по п.1, где антитело содержит последовательности вариабельного тяжелого (VH) и вариабельного легкого (VL) доменов антитела, продуцируемого гибридомой, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) в ATCC 7 марта 2006 года.4. Антитело по п.1, где антитело содержит последовательности вариабельного тяжелого (VH) и вариабельного легкого (VL) доменов антитела, продуцируемого гибридомой, депонированной Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.5. Антитело по п.1, где антитело является гуманизированной или химерной формой антитела против альфа5бета1, продуцируемого гибридомой, выбранной из группы, состоящей из гибридомы, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) и гибридомы, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.6. Антитело по любому из пп.1-5, где антитело связывается с человеческим альфа5бета1 с Kd между 500 нМ и 1 пМ.7. Антитело по п.1, где антитело не связывает альфаVбета3 или альфаVбета5 или альфаVбета1.8. Антитело по любому из п.п. 1 и 3-5, где антитело содержит последовательность Fc человеческого IgG.9. Антитело по любому из 1. An antibody that is capable of binding human alpha5beta1 and competitively inhibiting the binding of an anti-alpha5beta1 antibody to human alpha5beta1, where anti-alpha5beta1 antibodies are produced by a hybridoma selected from the group consisting of a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA- PTA- 7421) and hybridomas deposited as Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) at ATCC on March 7, 2006.2. The antibody of claim 1, wherein the antibody is produced by a hybridoma selected from the group consisting of a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) and a hybridoma deposited as Alpha5 / beta1 7H12.5.1.4 ( ATCC No. PTA-7420) at ATCC March 7, 2006. 3. The antibody of claim 1, wherein the antibody comprises the variable heavy (VH) and variable light (VL) domains of an antibody produced by a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) at ATCC on March 7, 2006 .4. The antibody according to claim 1, where the antibody contains the sequences of the variable heavy (VH) and variable light (VL) domains of the antibody produced by the hybridoma deposited Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) in ATCC March 7, 2006. 5. The antibody according to claim 1, wherein the antibody is a humanized or chimeric form of an anti-alpha5beta1 antibody produced by a hybridoma selected from the group consisting of a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) and a hybridoma deposited as Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) at ATCC March 7, 2006.6. An antibody according to any one of claims 1 to 5, wherein the antibody binds to human alpha5beta1 with a Kd of between 500 nM and 1 pM. The antibody according to claim 1, where the antibody does not bind alphaVbeta3 or alphaVbeta5 or alphaVbeta 1.8. Antibody according to any one of paragraphs. 1 and 3-5, where the antibody contains the Fc sequence of human IgG. 9. Antibody according to any one of

Claims (60)

1. Антитело, которое способно связывать человеческий альфа5бета1 и конкурентно подавлять связывание антитела против альфа5бета1 с человеческим альфа5бета1, где антитела против альфа5бета1 продуцируются гибридомой, выбранной из группы, состоящей из гибридомы, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) и гибридомы, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.1. An antibody that is capable of binding human alpha5beta1 and competitively inhibiting the binding of an anti-alpha5beta1 antibody to human alpha5beta1, where anti-alpha5beta1 antibodies are produced by a hybridoma selected from the group consisting of a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA- PTA- 7421) and hybridomas deposited as Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) at ATCC on March 7, 2006. 2. Антитело по п.1, где антитело продуцируется гибридомой, выбранной из группы, состоящей из гибридомы, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) и гибридомы, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.2. The antibody according to claim 1, where the antibody is produced by a hybridoma selected from the group consisting of a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) and a hybridoma deposited as Alpha5 / beta1 7H12.5.1. 4 (ATCC No. PTA-7420) at ATCC on March 7, 2006. 3. Антитело по п.1, где антитело содержит последовательности вариабельного тяжелого (VH) и вариабельного легкого (VL) доменов антитела, продуцируемого гибридомой, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) в ATCC 7 марта 2006 года.3. The antibody according to claim 1, where the antibody contains the sequences of the variable heavy (VH) and variable light (VL) domains of an antibody produced by a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) in ATCC March 7 2006 year. 4. Антитело по п.1, где антитело содержит последовательности вариабельного тяжелого (VH) и вариабельного легкого (VL) доменов антитела, продуцируемого гибридомой, депонированной Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.4. The antibody according to claim 1, where the antibody contains the sequences of the variable heavy (VH) and variable light (VL) domains of the antibody produced by the hybridoma deposited Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) in ATCC March 7, 2006 of the year. 5. Антитело по п.1, где антитело является гуманизированной или химерной формой антитела против альфа5бета1, продуцируемого гибридомой, выбранной из группы, состоящей из гибридомы, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) и гибридомы, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.5. The antibody according to claim 1, where the antibody is a humanized or chimeric form of an antibody against alpha5beta1 produced by a hybridoma selected from the group consisting of hybridomas deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) and hybridomas, deposited as Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) at ATCC on March 7, 2006. 6. Антитело по любому из пп.1-5, где антитело связывается с человеческим альфа5бета1 с Kd между 500 нМ и 1 пМ.6. The antibody according to any one of claims 1 to 5, wherein the antibody binds to human alpha5beta1 with a Kd of between 500 nM and 1 pM. 7. Антитело по п.1, где антитело не связывает альфаVбета3 или альфаVбета5 или альфаVбета1.7. The antibody according to claim 1, where the antibody does not bind alphaVbeta3 or alphaVbeta5 or alphaVbeta1. 8. Антитело по любому из п.п. 1 и 3-5, где антитело содержит последовательность Fc человеческого IgG.8. The antibody according to any one of paragraphs. 1 and 3-5, where the antibody contains the Fc sequence of human IgG. 9. Антитело по любому из п.п. 1 и 3-5, где антитело содержит последовательность Fc человеческого IgG1 или человеческого IgG4.9. The antibody according to any one of paragraphs. 1 and 3-5, where the antibody contains the Fc sequence of human IgG1 or human IgG4. 10. Антитело по п.8, где антитело включает последовательность Fc, не имеющую эффекторной функции антителозависимой клеточной цитотоксичности (ADCC).10. The antibody of claim 8, where the antibody includes an Fc sequence that does not have the effector function of antibody-dependent cell cytotoxicity (ADCC). 11. Антитело по любому из п.п.1 и 3-5, выбранное из группы, состоящей из Fab, Fab', F(ab)'2, одноцепочечного Fv (scFv), фрагмента Fv; диатела и линейного антитела.11. The antibody according to any one of claims 1 and 3-5, selected from the group consisting of Fab, Fab ', F (ab)' 2 , single-chain Fv (scFv), a Fv fragment; diabodies and linear antibodies. 12. Антитело по любому из п.п. 1 и 3-5, где антитело является мультиспецифичным антителом.12. The antibody according to any one of paragraphs. 1 and 3-5, where the antibody is a multispecific antibody. 13. Антитело по любому из п.п. 1 и 3-5, конъюгированное с терапевтическим препаратом.13. The antibody according to any one of paragraphs. 1 and 3-5 conjugated to a therapeutic drug. 14. Антитело по п.13, где терапевтический препарат выбран из группы, состоящей из цитотоксического препарата, радиоизотопа и химиотерапевтического препарата.14. The antibody of claim 13, wherein the therapeutic drug is selected from the group consisting of a cytotoxic drug, a radioisotope, and a chemotherapeutic drug. 15. Антитело по любому из п.п. 1 и 3-5, конъюгированное с меткой.15. The antibody according to any one of paragraphs. 1 and 3-5 conjugated to the label. 16. Антитело по п.15, где метка выбрана из группы, состоящей из радиоизотопа, флуоресцентного красителя и фермента.16. The antibody of claim 15, wherein the label is selected from the group consisting of a radioisotope, a fluorescent dye, and an enzyme. 17. Изолированная молекула нуклеиновой кислоты, кодирующая вариабельный домен тяжелой цепи (VH) или вариабельный домен легкой цепи (VL) или одновременно домены VH и VL любого из антител по п.п.1-5.17. An isolated nucleic acid molecule encoding a variable domain of a heavy chain (VH) or a variable domain of a light chain (VL) or simultaneously the VH and VL domains of any of the antibodies according to claims 1-5. 18. Экспрессионный вектор, кодирующий молекулу нуклеиновой кислоты по п.17.18. Expression vector encoding a nucleic acid molecule according to 17. 19. Клетка, содержащая молекулу нуклеиновой кислоты по п.17.19. A cell containing a nucleic acid molecule according to 17. 20. Клетка по п.19, где клетка является гибридомой, депонированной как Alpha5/beta1 7H5.4.2.8 (ATCC № PTA-7421) или гибридомой, депонированной как Alpha5/beta1 7H12.5.1.4 (ATCC № PTA-7420) в ATCC 7 марта 2006 года.20. The cell of claim 19, wherein the cell is a hybridoma deposited as Alpha5 / beta1 7H5.4.2.8 (ATCC No. PTA-7421) or a hybridoma deposited as Alpha5 / beta1 7H12.5.1.4 (ATCC No. PTA-7420) at ATCC March 7, 2006. 21. Способ получения антитела, включающий культивирование клеток по п.19 или по п.20 и выделение антител из клеточной культуры.21. A method for producing an antibody, comprising culturing the cells of claim 19 or claim 20 and isolating antibodies from the cell culture. 22. Композиция, включающая антитело по любому из пп.1 и 3-5, и фармацевтически приемлемый носитель.22. A composition comprising an antibody according to any one of claims 1 and 3-5, and a pharmaceutically acceptable carrier. 23. Способ обнаружения белка альфа5бета1 в образце от пациента путем контактирования образца с антителом по любому из пп.1-5 и обнаружения антитела против альфа5бета1, связанного с белком альфа5бета1.23. A method for detecting alpha5beta1 protein in a sample from a patient by contacting the sample with an antibody according to any one of claims 1-5 and detecting an anti-alpha5beta1 antibody bound to alpha5beta1 protein. 24. Способ по п.23, где антитело используется в иммуногистохимических исследованиях (ИГХ) или в исследованиях с использованием ИФА.24. The method according to item 23, where the antibody is used in immunohistochemical studies (IHC) or in studies using ELISA. 25. Применение антитела по любому из пп.1 и 3-5, при производстве лекарственного средства для ингибирования ангиогенеза и/или проницаемости сосудов у субъекта.25. The use of an antibody according to any one of claims 1 and 3-5, in the manufacture of a medicament for inhibiting angiogenesis and / or vascular permeability in a subject. 26. Применение антитела по любому из пп.1 и 3-5, при производстве лекарственного средства для лечения заболевания у субъекта, где заболевание сопровождается патологическим ангиогенезом или патологической проницаемостью сосудов.26. The use of antibodies according to any one of claims 1 and 3-5, in the manufacture of a medicament for the treatment of a disease in a subject, where the disease is accompanied by pathological angiogenesis or pathological vascular permeability. 27. Способ ингибирования ангиогенеза и/или проницаемости сосудов у субъекта, страдающего от заболевания, включающий введение антагониста VEGF и антагониста альфа5бета1.27. A method of inhibiting angiogenesis and / or vascular permeability in a subject suffering from a disease, comprising administering a VEGF antagonist and an alpha5beta antagonist. 28. Способ лечения рака у субъекта, включающий введение антагониста VEGF и антагониста альфа5бета1.28. A method of treating cancer in a subject, comprising administering a VEGF antagonist and an alpha5beta antagonist. 29. Способ лечения заболеваний глаз у субъекта, включающий введение антагониста VEGF и антагониста альфа5бета1.29. A method for treating eye diseases in a subject, comprising administering a VEGF antagonist and an alpha5beta antagonist. 30. Способ лечения аутоиммунных заболеваний у субъекта, включающий введение антагониста VEGF и антагониста альфа5бета1.30. A method for treating autoimmune diseases in a subject, comprising administering a VEGF antagonist and an alpha5beta1 antagonist. 31. Способ по любому из п.п.27-30, где субъекту вводят антагонист VEGF, а затем антагонист альфа5бета1.31. The method according to any one of claims 27-30, wherein the subject is administered a VEGF antagonist and then an alpha5beta1 antagonist. 32. Способ по любому из п.п.27-30, где антагонист VEGF и антагонист альфа5бета1 вводят субъекту одновременно.32. The method according to any one of claims 27-30, wherein the VEGF antagonist and alpha5beta1 antagonist are administered to the subject simultaneously. 33. Способ по п.27, где субъект страдает от заболевания, сопровождающегося патологическим ангиогенезом или патологической проницаемостью сосудов.33. The method according to item 27, where the subject suffers from a disease accompanied by pathological angiogenesis or pathological vascular permeability. 34. Способ по п.27, где заболевание выбрано из группы, состоящей из опухоли, иммунного заболевания или заболевания глаза.34. The method according to item 27, where the disease is selected from the group consisting of a tumor, immune disease or eye disease. 35. Способ по любому из п.п.27-30, где субъект подвергается лечению антагонистом VEGF до тех пор, пока субъект не перестает реагировать на лечение антагонистом VEGF, после чего субъект подвергается лечению антагонистом альфа5бета1.35. The method according to any one of claims 27-30, wherein the subject is treated with a VEGF antagonist until the subject ceases to respond to treatment with a VEGF antagonist, after which the subject is treated with an alpha5beta antagonist. 36. Способ по п.28, где субъект подвергается лечению антагонистом VEGF, когда рак не является инвазивным и лечению антагонистом альфа5бета1, когда рак является инвазивным.36. The method of claim 28, wherein the subject is treated with a VEGF antagonist when the cancer is not invasive and treated with an alpha5beta1 antagonist when the cancer is invasive. 37. Способ по п.27, где субъект имеет повышенные уровни альфа5бета1 в пораженной ткани по сравнению с тканью субъекта, не страдающего от болезни.37. The method according to item 27, where the subject has elevated levels of alpha5beta1 in the affected tissue compared with the tissue of a subject not suffering from a disease. 38. Способ по любому из п.п.27-30, где субъекту дополнительно вводят терапевтический препарат, выбранный из группы, состоящей из анти-неопластичесого препарата, химиотерапевтического препарата, рост-ингибирующего препарата и цитотоксического препарата.38. The method according to any one of claims 27-30, wherein the subject is further administered a therapeutic drug selected from the group consisting of an anti-neoplastic drug, a chemotherapeutic drug, a growth inhibitory drug, and a cytotoxic drug. 39. Способ по любому из п.п.27-30, где связывание антител против VEGF с человеческим VEGF может быть полностью ингибировано антителом Avastin®.39. The method according to any one of claims 27-30, wherein the binding of anti-VEGF antibodies to human VEGF can be completely inhibited by an Avastin® antibody. 40. Способ по п.42, где антитело против VEGF является антителом Avastin®.40. The method according to § 42, where the anti-VEGF antibody is an Avastin® antibody. 41. Способ по любому из п.п.27-30, где антагонист альфа5бета1 конъюгирован с цитотоксическим препаратом.41. The method according to any one of claims 27-30, wherein the alpha5beta1 antagonist is conjugated to a cytotoxic drug. 42. Способ по п.41, где цитотоксический препарат является радиоактивным изотопом, химиотерапевтическим препаратом или токсином.42. The method according to paragraph 41, where the cytotoxic drug is a radioactive isotope, chemotherapeutic drug or toxin. 43. Способ по любому из п.п.27-30, где антагонист VEGF является антителом.43. The method according to any one of claims 27-30, wherein the VEGF antagonist is an antibody. 44. Способ по любому из п.п.27-30, где антагонист альфа5бета1 является антителом.44. The method according to any one of claims 27-30, wherein the alpha5beta1 antagonist is an antibody. 45. Способ по п.43, где антитело против VEGF является гуманизированным или человеческим антителом.45. The method according to item 43, where the anti-VEGF antibody is a humanized or human antibody. 46. Способ по п.44, где антитело против альфа5бета1 является гуманизированным или человеческим антителом.46. The method of claim 44, wherein the anti-alpha5beta1 antibody is a humanized or human antibody. 47. Композиция, содержащая антагонист VEGF, антагонист альфа5бета1 и фармацевтически приемлемый ингибитор.47. A composition comprising a VEGF antagonist, an alpha5beta1 antagonist and a pharmaceutically acceptable inhibitor. 48. Набор, содержащий инструкции по обнаружению альфа5бета1 у субъекта, который подвергался лечению антагонистом VEGF.48. A kit containing instructions for detecting alpha5beta1 in a subject who has been treated with a VEGF antagonist. 49. Применение композиции по п.47 при производстве лекарственного средства для ингибирования ангиогенеза и/или сосудистой проницаемости у субъекта, страдающего заболеванием.49. The use of the composition of claim 47 in the manufacture of a medicament for inhibiting angiogenesis and / or vascular permeability in a subject suffering from a disease. 50. Применение по п.49, где заболевание выбрано из группы, состоящей из рака, заболевания глаза и аутоиммунного заболевания у субъекта.50. The use of claim 49, wherein the disease is selected from the group consisting of cancer, eye disease, and an autoimmune disease in a subject. 51. Применение по п.49, где заболевание выбрано из группы, состоящей из солидной опухоли, метастатической опухоли, опухоли мягких тканей, заболевания, связанного с неоваскуляризацией глаза, воспалительного заболевания, сопровождаемого патологическим ангиогенезом, заболевания, возникающего после трансплантации субъекту и заболевания, сопровождающегося патологическим развитием сосудисто-волокнистой ткани.51. The use of claim 49, wherein the disease is selected from the group consisting of a solid tumor, metastatic tumor, soft tissue tumor, a disease associated with neovascularization of the eye, an inflammatory disease accompanied by pathological angiogenesis, a disease that occurs after transplantation to a subject and a disease accompanied pathological development of vascular fibrous tissue. 52. Применение по п.50, где рак выбран из группы, состоящей из рака груди, рака шейки матки, рака кишечника, рака легких, неходжскинской лимфомы (NHL), почечноклеточного рака, рака простаты, рака печени, рака головы и шеи, меланомы, рака яичника, мезотелиомы, рака мягких тканей и множественной миеломы.52. The application of claim 50, wherein the cancer is selected from the group consisting of breast cancer, cervical cancer, intestinal cancer, lung cancer, non-Hodgkin lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, head and neck cancer, melanoma , ovarian cancer, mesothelioma, soft tissue cancer and multiple myeloma. 53. Применение по п.49, где заболевание выбрано из группы, состоящей из ретинопатии, вызванной возрастом дегенерации желтого пятна, рубеоза; псориаза, псориатического артрита и воспалительных заболеваний почек, гемолитического уремического синдрома, диабетической нефропатии, артрита, воспалительной болезни кишечника, хронического воспаления, хронического отслоения сетчатки, хронического увеита, отторжения трансплантата роговицы, неоваскуляризации роговицы, неоваскуляризации трансплантата роговицы, болезни Крона, миопии, глазной неоваскулярной болезни, остеоартритов, болезни Педжета, пемфигоида, полиартрита, пост-лазерной радиальной кератотомии, неоваскуляризации сетчатки, синдрома Шегрена, язвенного колита, отторжения трансплантанта, воспаления легких, нефротического синдрома, отека, асцитов, ассоциированных со злокачественными опухолями, удара, ангиофибромы и неоваскулярной глаукомы.53. The use of claim 49, wherein the disease is selected from the group consisting of retinopathy caused by age-related macular degeneration, rubeosis; psoriasis, psoriatic arthritis and inflammatory kidney diseases, hemolytic uremic syndrome, diabetic nephropathy, arthritis, inflammatory bowel disease, chronic inflammation, chronic retinal detachment, chronic uveitis, corneal transplant rejection, corneal neovascularization, corneal neovascularization, corneal transplant neovascularization, neovascularization, diseases, osteoarthritis, Paget's disease, pemphigoid, polyarthritis, post-laser radial keratotomy, set neovascularization atki, Sjogren's syndrome, ulcerative colitis, graft rejection, lung inflammation, nephrotic syndrome, edema, ascites associated with malignancies, stroke, angiofibroma and neovascular glaucoma. 54. Применение антагониста альфа5бета при производстве лекарственного средства для лечения субъекта, страдающего от заболевания, где субъект реагировал на лечение заболевания антагонистом VEGF, но частично или полностью перестал реагировать на антагонист VEGF.54. The use of an alpha5bet antagonist in the manufacture of a medicament for the treatment of a subject suffering from a disease, where the subject responded to the treatment of the disease with a VEGF antagonist but partially or completely stopped responding to the VEGF antagonist. 55. Применение по п.54, где субъект имеет повышенные уровни альфа5бета1 в пораженной болезнью ткани по сравнению с субъектом, не страдающим заболеванием.55. The application of claim 54, wherein the subject has elevated levels of alpha5beta1 in the diseased tissue compared to the subject not suffering from the disease. 56. Применение по п.54, где субъекту дополнительно вводится терапевтический препарат, выбранный из группы, состоящей из антинеопластического препарата, химиотерапевтического препарата, рост-ингибирующего препарата и цитотоксического агента.56. The application of claim 54, wherein the subject is additionally administered a therapeutic drug selected from the group consisting of an antineoplastic drug, a chemotherapeutic drug, a growth inhibitory drug, and a cytotoxic agent. 57. Применение антагониста VEGF при производстве лекарственного средства для лечения субъекта, страдающего от заболевания, где субъект реагировал на лечение заболевания антагонистом альфа5бета1, но частично или полностью перестал реагировать на антагонист альфа5бета1.57. The use of a VEGF antagonist in the manufacture of a medicament for the treatment of a subject suffering from a disease, where the subject responded to treatment of the disease with an alpha5beta1 antagonist but partially or completely stopped responding to an alpha5beta1 antagonist. 58. Композиция, включающая агонист VEGF и агонист альфа5бета1.58. A composition comprising a VEGF agonist and an alpha5beta1 agonist. 59. Применение композиции по п.58 при производстве лекарственного средства.59. The use of the composition according to p. 58 in the manufacture of a medicinal product. 60. Применение по п.59, где лекарственное средство ускоряет заживление ран. 60. The use of claim 59, wherein the drug accelerates wound healing.
RU2012129350/10A 2006-03-21 2012-07-11 COMBINED THERAPY USING ALPHA 5BETA1 ANTAGONISTS RU2012129350A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78470406P 2006-03-21 2006-03-21
US60/784,704 2006-03-21
US78533006P 2006-03-22 2006-03-22
US60/785,330 2006-03-22
US87174306P 2006-12-22 2006-12-22
US60/871,743 2006-12-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2008141706/10A Division RU2465282C2 (en) 2006-03-21 2007-03-21 Combined therapy with using alpha5beta1 antagonists

Publications (1)

Publication Number Publication Date
RU2012129350A true RU2012129350A (en) 2014-01-20

Family

ID=39402298

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012129350/10A RU2012129350A (en) 2006-03-21 2012-07-11 COMBINED THERAPY USING ALPHA 5BETA1 ANTAGONISTS

Country Status (27)

Country Link
US (3) US20090220504A1 (en)
EP (2) EP1989231B1 (en)
JP (2) JP5298007B2 (en)
KR (1) KR101454491B1 (en)
AR (1) AR060040A1 (en)
AU (1) AU2007319757B2 (en)
BR (1) BRPI0709338A2 (en)
CA (1) CA2646611A1 (en)
CR (1) CR10311A (en)
DK (1) DK1989231T3 (en)
EC (1) ECSP088835A (en)
ES (1) ES2544957T3 (en)
HR (1) HRP20150884T1 (en)
HU (1) HUE025989T2 (en)
IL (1) IL193926A (en)
MA (1) MA30384B1 (en)
MX (1) MX2008011905A (en)
MY (1) MY159375A (en)
NO (1) NO20084396L (en)
NZ (3) NZ598594A (en)
PL (1) PL1989231T3 (en)
PT (1) PT1989231E (en)
RS (1) RS54156B1 (en)
RU (1) RU2012129350A (en)
TW (1) TWI397535B (en)
UA (1) UA100969C2 (en)
WO (1) WO2008060645A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
CA2652886A1 (en) * 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity
EP2193148A2 (en) * 2007-07-27 2010-06-09 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
HRP20160308T1 (en) * 2007-09-26 2016-04-22 Genentech, Inc. NEW ANTIBODIES
EP2641612A1 (en) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
JP6051048B2 (en) * 2009-03-25 2016-12-21 ジェネンテック， インコーポレイテッド Novel anti-α5β1 antibody and use thereof
AU2012230809B2 (en) * 2011-03-23 2017-06-29 The Regents Of The University Of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
WO2013025936A1 (en) * 2011-08-18 2013-02-21 Cornell University Detection and treatment of metastatic disease
KR102023401B1 (en) 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 Multi-specific monoclonal antibodies
JP6538561B2 (en) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド Anti-complement C1s antibodies and their uses
PT2914291T (en) * 2012-11-02 2022-05-05 Bioverativ Usa Inc Anti-complement c1s antibodies and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (en) 2015-12-30 2018-10-26 科达制药股份有限公司 Antibody and its conjugate
FI3525583T3 (en) 2016-10-12 2025-10-31 Bioverativ Usa Inc ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
BR112019012071A2 (en) 2016-12-14 2019-11-12 Progenity Inc treating a gastrointestinal tract disease with an integrin inhibitor
JP7370252B2 (en) 2017-05-30 2023-10-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Treatment of neuroinflammatory diseases
EP4495136A3 (en) 2018-01-26 2025-04-23 The Regents of the University of California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
KR20210009421A (en) 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 Multispecific antibody construct
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114867487A (en) 2019-11-25 2022-08-05 加利福尼亚大学董事会 Long-acting VEGF inhibitors for intraocular neovascularization
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN119161478A (en) * 2021-05-11 2024-12-20 帕西西娅治疗公司 α5β1 integrin binding agent and its use
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
ATE97498T1 (en) 1984-01-30 1993-12-15 Imp Cancer Res Tech IMPROVEMENTS IN GROWTH FACTORS.
US5540933A (en) * 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
NZ229700A (en) 1988-06-24 1993-01-27 Dow Chemical Co Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments
CN1033030C (en) 1988-06-24 1996-10-16 唐化学原料公司 Preparation method of macrocyclic bifunctional chelating agent and its complexes and antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
DE68926248T2 (en) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "new" human protein and the use of this protein for the detection of preneoplasmic or neoplasmic in humans
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
PL174494B1 (en) 1992-11-13 1998-08-31 Idec Pharma Corp Therapeutic application of chimeric and radiotracer labelled antibodies, directed against the differentation antigen limited to human lymphocytes b, for treating lymphoma from lymphocytes b
US5627263A (en) * 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
PT719859E (en) * 1994-12-20 2003-11-28 Merck Patent Gmbh ANTI-ALPHA MONOCLONAL ANTIBODY V-INTEGRINA
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
PT1516628E (en) 1995-07-27 2013-09-24 Genentech Inc Stable isotonic lyophilized protein formulation
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
WO1998022617A1 (en) 1996-11-21 1998-05-28 The Regents Of The University Of Michigan Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
JP3957765B2 (en) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド Anti-VEGF antibody
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
DE69930723T2 (en) 1998-01-23 2006-11-16 Merck Patent Gmbh USE OF ANTIBODY 271.14D9.F8 (DSM ACC2331) TO REDUCE BINDING BETWEEN ALPHAVBETA6 INTEGRIN AND FIBRONECTIN IN VITRO
JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2327451B1 (en) 1998-05-08 2013-10-23 The Regents of the University of California Method for detecting and inhibiting angiogenesis
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
ES2694002T3 (en) 1999-01-15 2018-12-17 Genentech, Inc. Polypeptide comprising an Fc region of variant human IgG1
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US20020019330A1 (en) * 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20020015970A1 (en) * 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040009494A1 (en) * 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
MXPA02001439A (en) 1999-08-11 2002-08-30 Eos Biotechnology Inc Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators.
US20030152926A1 (en) * 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
WO2002079492A2 (en) 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
JP2005527180A (en) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド Lung cancer diagnosis method, composition of lung cancer modifier and screening method
WO2002098358A2 (en) 2001-06-04 2002-12-12 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
AU2002347428A1 (en) 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) * 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc CANCER DIAGNOSTIC METHODS, COMPOSITIONS AND METHODS FOR SCREENING CANCER MODULATORS
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2003256307A1 (en) * 2002-06-25 2004-01-06 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
RU2346701C2 (en) * 2002-11-26 2009-02-20 ПиДиЭл БАЙОФАРМА ИНК. CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
NZ591970A (en) * 2003-01-22 2012-11-30 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
EP1625165A2 (en) * 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7194111B1 (en) * 2003-07-10 2007-03-20 The United States Of America As Represented By The Secretary Of The Navy Hyperspectral remote sensing systems and methods using covariance equalization
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
KR20070009637A (en) * 2004-03-24 2007-01-18 피디엘 바이오파르마 인코포레이티드 Use of antiα5β1 antibodies to inhibit cancer cell proliferation
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
ES2539126T3 (en) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Anti integrin immunoconjugates, methods for their production and use
US20090111828A1 (en) * 2005-11-23 2009-04-30 Astrazeneca Ab L-alanine derivatives
US20090137601A1 (en) * 2005-11-23 2009-05-28 Astrazeneca Ab L-Phenylalanine Derivatives
EP1984330A1 (en) 2006-02-09 2008-10-29 AstraZeneca AB Chemical compounds
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
CA2652886A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-.alpha.5.beta.1 integrin function blocking antibodies with reduced immunogenicity

Also Published As

Publication number Publication date
PL1989231T3 (en) 2015-10-30
TW200813090A (en) 2008-03-16
IL193926A (en) 2015-05-31
EP2366716A3 (en) 2011-11-16
US20090220504A1 (en) 2009-09-03
ECSP088835A (en) 2008-11-27
MA30384B1 (en) 2009-05-04
KR20080113246A (en) 2008-12-29
AU2007319757B2 (en) 2013-09-19
EP1989231A2 (en) 2008-11-12
JP5298007B2 (en) 2013-09-25
AU2007319757A1 (en) 2008-05-22
MY159375A (en) 2016-12-30
US8350010B2 (en) 2013-01-08
AR060040A1 (en) 2008-05-21
RS54156B1 (en) 2015-12-31
NZ571068A (en) 2012-06-29
PT1989231E (en) 2015-09-18
EP1989231B1 (en) 2015-05-20
JP2009536921A (en) 2009-10-22
HUE025989T2 (en) 2016-05-30
BRPI0709338A2 (en) 2011-07-12
EP2366716A2 (en) 2011-09-21
WO2008060645A2 (en) 2008-05-22
IL193926A0 (en) 2011-08-01
KR101454491B1 (en) 2014-10-29
CA2646611A1 (en) 2008-05-22
UA100969C2 (en) 2013-02-25
MX2008011905A (en) 2008-09-30
US20120195908A1 (en) 2012-08-02
NZ615012A (en) 2015-11-27
JP2013155178A (en) 2013-08-15
WO2008060645A3 (en) 2008-12-04
HRP20150884T1 (en) 2015-09-25
ES2544957T3 (en) 2015-09-07
DK1989231T3 (en) 2015-08-24
US20140004038A1 (en) 2014-01-02
NO20084396L (en) 2008-12-16
TWI397535B (en) 2013-06-01
NZ598594A (en) 2014-01-31
CR10311A (en) 2009-01-20

Similar Documents

Publication Publication Date Title
RU2012129350A (en) COMBINED THERAPY USING ALPHA 5BETA1 ANTAGONISTS
JP2009536921A5 (en)
RU2010116184A (en) NEW ANTIBODIES
JP2012521218A5 (en)
CN113544156A (en) Anti-Claudin18.2 antibody and its application
JP2011501656A5 (en)
KR20180088445A (en) Novel anti-claudin antibodies and methods of use
JP2020522280A5 (en)
JP2020522281A5 (en)
JP2024514109A (en) Anti-CNTN4 antibody and its use
US20210292416A1 (en) Bispecific antibodies targeting immune checkpoints
JP2024511358A (en) How to treat cancer with PDGFRα inhibitors
US20100151486A1 (en) Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof
EP2270053A1 (en) Humanized AXL antibodies
JP2021516670A (en) Anti-TRAILR2 antibody-toxin-complex and its drug use in antitumor treatment
RU2761638C1 (en) Antibodies against the programmed death ligand (pd-l1) and application thereof
RU2008141706A (en) COMBINED THERAPY USING ALPHA 5BETA1 ANTAGONISTS
KR20250019077A (en) Anti-CD40 antibody and anti-PD-L1×CD40 bispecific antibody and uses thereof
CN113597432B (en) anti-EpCAM antibodies and uses thereof
MXPA06009759A (en) Target for b-cell disorders.
CN116514966A (en) anti-DKK 1 antibody, pharmaceutical composition and application thereof
CA3206472A1 (en) Anti-trpv6 monoclonal antibody and application thereof
CN113373118A (en) Hybridoma cell strain, monoclonal antibody and application thereof
CN117430710B (en) A monoclonal antibody targeting Trop2 and its application
EP4582450A1 (en) Anti-pvrig antibody and application thereof

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20150713